Hi there,
Rapamycin has drawn interest in longevity medicine because it inhibits mTOR, a pathway involved in growth and cellular maintenance. It has extended lifespan in several animal models. Human benefits and the best dosing schedule remain uncertain.
A 2026 laboratory study added an interesting finding about human immune cells.
Researchers exposed isolated human T cells to a DNA-damaging agent and studied how rapamycin changed the response.
The treated cells had less DNA damage and better survival in those experiments. A small human component also examined immune-cell markers.
That suggests another mechanism worth studying, not proof that a weekly tablet protects a person’s DNA or extends life.
I prescribe rapamycin to selected patients after discussing the uncertainties. I don’t prescribe it to most. The evidence and safety questions below explain why.
Let's look at the data.
The TL;DR:
- Human evidence: Small trials and tissue studies raise useful questions, but they do not establish human lifespan extension.
- My practice: Selected off-label use with patient-specific monitoring, rather than a validated longevity dose.
- Safety: Lipid and glucose changes deserve assessment; they should not be dismissed as signs that the drug is working.
🧬 Why Rapamycin for Longevity?
Rapamycin has extended lifespan in several laboratory species, with effects that vary by dose, sex, and model. Disease-model results help build hypotheses; they do not show that it prevents those diseases in healthy people.
But we lacked the definitivehuman data to prove it wasn’t just a quirk of animal biology.
Human work now includes immune, skin, and body-composition outcomes. Some results are encouraging, others are null. None of these trials establishes a broad tissue-preservation or longevity effect.
1. Immune outcomes: promising and mixed
For decades, doctors feared Rapamycin was purely "immunosuppressive" (due to its use in transplants to prevent rejection).
Some low-dose mTOR-inhibitor trials improved selected immune measures. That doesn’t erase immunosuppressive risks or prove that any pulsed rapamycin schedule rejuvenates immunity.
Earlier studies of everolimus and other mTOR inhibitors reported improved vaccine responses or fewer respiratory infections. A later phase 3 trial of RTB101 did not reduce its primary outcome of clinically symptomatic respiratory illness. These are related compounds and specific outcomes, not proof of immune rejuvenation from weekly sirolimus.
2. PEARL: secondary findings after a null primary result
The “Participatory Evaluation of Aging with Rapamycin for Longevity” (PEARL) study examined healthy older adults in a 48-week randomized, double-blind, placebo-controlled trial.
PEARL did not improve its primary outcome, visceral fat. Women in the 10 mg compounded-rapamycin group had improvements in secondary lean-mass and pain measures. Those findings need replication. Differences in absorption do not justify converting that dose to an exact generic-tablet equivalent, or assuming men needed a larger dose.
3. Topical skin research
Skin is the most visible sign of aging. In 2019, researchers at Drexel University showed rapamycin's topical effects are more than just skin deep.
A small topical study found changes in p16 and collagen VII in treated skin over eight months. It was exploratory and local. It doesn’t show that oral rapamycin clears senescent cells or repairs tissues throughout the body.
4. Ovarian-aging research
Ovarian reserve and reproductive aging are important areas of study, including for women who do not plan a pregnancy.
VIBRANT was designed to study ovarian-reserve markers with low-dose rapamycin. Preliminary reports do not establish a five-year delay in menopause or protection of bones, brain, and heart. Those would need longer-term outcomes.
5. ME/CFS: pilot evidence
A 2025 pilot study examined symptoms and autophagy-related measures in people with ME/CFS.
Participants reported improvements in fatigue and post-exertional symptoms. Without a placebo comparison, that cannot establish efficacy. The study did not demonstrate that rapamycin cleared damaged material from participants’ neurons.
6. DNA damage: cells and a very small human study
The 2026 Aging Cell paper studied isolated T cells and included four rapamycin-treated participants and five controls.
Cell experiments found less DNA damage and better survival after a specific chemical challenge. The human component found changes in selected immune and senescence markers; some DNA-damage results were trends rather than significant differences. That is not evidence that rapamycin prevents cancer, protects astronauts, or repairs DNA throughout a person’s body.
Subscribe or share our newsletter for longevity updates
How I approach off-label prescribing
Rapamycin is a prescription drug with important risks and interactions. Its use for longevity is off-label. The doses below describe my practice in February 2026. They are not instructions to start treatment yourself.
Reading the studies is one thing; applying them to a living, breathing human is another.
In medicine, context is everything. Transplant patients take rapamycin daily. Their goal is immunosuppression: keeping the drug levels constantly high to prevent the body from rejecting a new organ.
For selected longevity patients, I consider a lower intermittent schedule. The aim is different from transplant care, but we don’t know a dose that reliably rejuvenates human immunity.
The pulse-and-recovery rationale is a hypothesis. Weekly dosing does not guarantee complete washout, autophagy activation, or DNA repair.
These are the factors I review:
Starting cautiously
At the time of this issue, I typically started selected patients at 1 or 2 mg weekly to assess tolerance. The right plan depends on the patient; this is not an approved longevity starting dose.
Mouth sores, infections, and other symptoms need review. Mouth sores are not automatically harmless or proof that the dose is too high. Related mTOR-inhibitor trials do not establish that weekly sirolimus is superior to all daily regimens.
2. The Individual Targeted Dose
I described gradual changes over two to three months and considered lean mass along with other patient factors. A lean-mass dosing formula for longevity has not been validated.
In that practice account, my usual upper targets were 6 mg weekly for women and 10 mg weekly for men. These were my choices, not evidence-based sex-specific equivalents or targets for readers.
Body size, liver function, drug interactions, formulation, and individual absorption can all affect exposure.
A 10 mg dose in a larger man does not reliably equal a 6 mg dose in a smaller woman. We cannot infer a useful peak or benefit from body size alone.
3. The Absorption Details
Formulation, food, and interacting medicines can change exposure.
Food: The label advises taking it consistently with or without food. Effects differ by formulation; one “fat multiplier” is not reliable for every product.
Interactions: Avoid grapefruit and review CYP3A4/P-gp inhibitors and inducers with the prescriber or pharmacist.
Illness or surgery: Infection and wound-healing concerns need an individual plan. Contact the prescriber rather than using a general skip-or-stop rule from an article.
Monitoring: What We Watch For
I review symptoms and blood tests because adverse effects can occur even when the intended dose is low.
1. Subjective Side Effects (What You Feel)
- Mouth sores or rash: Report them; the prescriber decides whether to pause or change treatment.
- Infection or poor wound healing: Seek review promptly. Weekly rapamycin is not proved to protect against flu or COVID.
- Breathing symptoms: The drug can cause noninfectious lung inflammation, which needs assessment.
2. Objective Biomarkers (What The Blood Shows)
Lipids: LDL and triglyceride rises are adverse findings to assess, not automatically benign signs of fat burning.
Glucose and HbA1c: A rise needs clinical review. Low fasting insulin does not make high glucose “benevolent pseudo-diabetes” or prove adequate insulin sensitivity.
Blood counts, kidney and liver function: Monitoring depends on the patient and regimen. Testing reduces uncertainty; it does not make an unproven longevity treatment risk-free.
Rapamycin is a high potential longevity intervention, but it is far from being fully-proven. I don’t actually prescribe it for the majority of my own patients; only to those who thoroughly understand the risk-benefit ratio and came to the decision after education.
⚡ Longevity Quick Hits
🧬 ER-phagy research: A Nature Cell Biology study examined how endoplasmic-reticulum remodeling relates to cell aging. It raises another mechanism to study.
It doesn’t show that fasting or rapamycin fails in people whenever that process is impaired, or establish a treatment based on FAM134B.
🧠 Aging anxiety and an age score: A study of 726 women examined anxiety and epigenetic-age measures.
Related research: aging-anxiety study.
The cumulative-anxiety association with DunedinPACE weakened and was no longer statistically significant after health and behavior adjustment. The study does not show that worrying about an age test makes you age faster.
⚡ The "Living Drug" Pivot: Klotho Avant Technologies has a new "cell-in-a-box" encapsulation technology designed to deliver Klotho (the famous "anti-aging protein") continuously into the bloodstream.
Avant’s announcement describes a development program. It doesn’t establish a successful human longevity therapy. Evidence from Klotho-overexpressing mice cannot show that a human implant will be safe or extend life.
🫀 Until Next Week
I’m interested in these results, but the studies used different compounds, routes, and designs. They don’t add up to six proven longevity benefits in people.
We need larger clinical trials with outcomes that matter to patients.
I still don’t prescribe it to most patients. Understanding the uncertainty and monitoring are necessary; they don’t settle whether the benefit will outweigh the risk.
If that's you, bring this newsletter to your doctor. That's why I wrote it this way.
The following issue looks at exercise and lifelong fitness.
To your healthspan,
Hillary Lin, MD
Co-Founder & CEO
Curator
Learn about Curator’s platform.
Events listed when this issue was published
I'll be at the Integrative Healthcare Symposium in NYC – Feb 19-21. Let me know if you're there and we can sync up!
👱🏻♀️👩🏻🦰👩🏻👧🏽👧🏾 Livelong Women’s Health Summit – April 17-18, 2026, SF, CA. Delighted to join 50 other thought leaders in speaking on women's longevity! (Code HILLARY50 for $50 off)
Offers listed when this issue was published
This issue included an affiliate offer from NeuroAgeTx. I may earn a commission from qualifying purchases. Check current services and prices before buying.
This issue included a Timeline offer. A four-week urolithin A trial found changes in selected immune-cell measures, not proof of longer life or fewer infections. Check current offer terms.
GlycanAge reports an age estimate from IgG glycosylation. It doesn’t diagnose the cause of inflammation or establish a treatment.
I have liked ZBiotics products. That preference is not proof that they extend life or offset alcohol’s health risks. Check current offer terms.
Unsubscribe · Preferences
The Longevity Letter
A weekly read on tests, treatment, and claims.
New issues look at what the evidence supports, what is premature, and what to skip.